Literature DB >> 3014998

Treatment of mitochondrial myopathy due to complex III deficiency with vitamins K3 and C: A 31P-NMR follow-up study.

Z Argov, W J Bank, J Maris, S Eleff, N G Kennaway, R E Olson, B Chance.   

Abstract

A patient with mitochondrial myopathy due to complex III deficiency who was treated with vitamin K3 (menadiol sodium diphosphate, 40 mg daily) and vitamin C showed clinical improvement. A 1-year study with phosphorus 31 nuclear magnetic resonance (31P-NMR) monitoring has shown that clinical and metabolic improvement was maintained by this therapy; increasing the dose of vitamin K3 to 80 mg daily improved the bioenergetic state of the patient's muscles at rest; postexercise recovery was less responsive to the increased dose; and a higher dose of vitamin K3 (80 mg/day) did not produce side effects. The differential therapeutic effects of vitamin K3 at rest and during exercise recovery are probably due to the differential kinetics of each metabolic state. Monitoring muscle bioenergetics with 31P-NMR is valuable in documenting therapeutic improvements in mitochondrial myopathies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014998     DOI: 10.1002/ana.410190615

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  19 in total

Review 1.  Mitochondrial myopathies.

Authors:  S DiMauro; E Bonilla; M Zeviani; S Servidei; D C DeVivo; E A Schon
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

2.  Defects in oxidative phosphorylation. Biochemical investigations in skeletal muscle and expression of the lesion in other cells.

Authors:  H R Scholte; H F Busch; I E Luyt-Houwen; M H Vaandrager-Verduin; H Przyrembel; W F Arts
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

Review 3.  Mitochondrial energetics and therapeutics.

Authors:  Douglas C Wallace; Weiwei Fan; Vincent Procaccio
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

Review 4.  Improving the physiological realism of experimental models.

Authors:  Kalyan C Vinnakota; Chae Y Cha; Patrik Rorsman; Robert S Balaban; Andre La Gerche; Richard Wade-Martins; Daniel A Beard; Jeroen A L Jeneson
Journal:  Interface Focus       Date:  2016-04-06       Impact factor: 3.906

5.  Why are there no proven therapies for genetic mitochondrial diseases?

Authors:  Peter W Stacpoole
Journal:  Mitochondrion       Date:  2011-05-13       Impact factor: 4.160

6.  Design and implementation of the first randomized controlled trial of coenzyme CoQ₁₀ in children with primary mitochondrial diseases.

Authors:  Peter W Stacpoole; Ton J deGrauw; Annette S Feigenbaum; Charles Hoppel; Douglas S Kerr; Shawn E McCandless; Michael V Miles; Brian H Robinson; Peter H Tang
Journal:  Mitochondrion       Date:  2012-09-25       Impact factor: 4.160

Review 7.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

Review 8.  Mitochondrial encephalomyopathies: what next?

Authors:  S DiMauro
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

Review 9.  Applications of magnetic resonance spectroscopy to diagnosis and monitoring of mitochondrial disease.

Authors:  P M Matthews; T Taivassalo
Journal:  Ital J Neurol Sci       Date:  1997-12

Review 10.  The biochemical basis of mitochondrial diseases.

Authors:  H R Scholte
Journal:  J Bioenerg Biomembr       Date:  1988-04       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.